Product
FE 999326
Aliases
nadofaragene firadenovec
1 clinical trial
1 indication
Indication
Bladder CancerClinical trial
A Phase 3, Open Label Trial to Evaluate the Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)Status: Recruiting, Estimated PCD: 2024-12-27